Defence Therapeutics to Showcase Accum® Intracellular Delivery Platform at World ADC Europe 2026
核心洞察
Defence Therapeutics (搜索) will present its proprietary Accum® (搜索) platform at World ADC Europe 2026, a breakthrough intracellular delivery technology designed to transport biologic payloads to their intended intracellular and nuclear targets.
The platform aims to unlock the full potential of antibody-drug conjugates and other complex cancer biologics by increasing intracellular potency and reducing therapeutic doses required.
The company seeks strategic partnerships with pharmaceutical and biotechnology companies to co-develop Accum® (搜索)-enabled ADCs and precision oncology biologics.
Defence Therapeutics (搜索) Inc. announced it will present at World ADC Europe 2026, taking place February 23-26, 2026, in London, UK, to showcase its proprietary Accum® (搜索) platform. The Montreal-based biotechnology company will demonstrate its breakthrough intracellular delivery technology designed to actively transport biologic payloads to their intended intracellular and nuclear targets.
The Accum® (搜索) platform represents a significant advancement in precision drug delivery, specifically engineered to unlock the full potential of antibody-drug conjugates (ADCs) and other complex cancer biologics. The technology works by increasing intracellular potency while reducing the doses required to achieve therapeutic efficacy, potentially addressing key challenges in current cancer treatment approaches.
Strategic Partnership Focus
At the conference, Defence aims to engage with pharmaceutical and biotechnology companies to advance strategic partnering discussions around co-developing Accum® (搜索)-enabled ADCs and precision oncology biologics. The company seeks to leverage its platform to enhance intracellular delivery and therapeutic performance across various cancer treatment modalities.
"At Defence, our mission is to transform advanced biologics into safer, more effective first-line cancer therapies through precision intracellular delivery," said Sébastien Plouffe, CEO of Defence Therapeutics (搜索). "World ADC Europe is a premier global forum to engage with innovators and potential partners who share our vision of a future where every cancer therapy reaches its full potential."
World Cancer Day Commitment
The announcement coincides with World Cancer Day, emphasizing Defence's commitment to accelerating next-generation cancer therapies that address critical unmet medical needs. "On World Cancer Day, we are reminded of the urgency to bring smarter, more precise cancer treatments to patients," added Plouffe. "Accum® (搜索) has the potential to help cancer therapies reach their full potential and deliver better outcomes for patients."
Technology Platform
Defence Therapeutics (搜索) positions itself as a precision intracellular drug-delivery company committed to making cancer treatment more effective and safer. The Accum® (搜索) precision drug delivery platform is designed to enhance the potency of ADCs and other complex biologics at lower doses, with the goal of reducing side effects and improving access to advanced therapies.
The company's approach focuses on cutting-edge science and collaboration with pharmaceutical and biotechnology partners to bring transformative therapies to patients. Defence Therapeutics (搜索) trades on multiple exchanges including CSE (DTC), FSE (DTC), and OTCQB (DTCFF).